tiprankstipranks
Advertisement
Advertisement
Inhibrx’s cancer drug drawing interest from Merck, Ono, Reuters says
PremiumThe FlyInhibrx’s cancer drug drawing interest from Merck, Ono, Reuters says
3d ago
Inhibrx up 39% at $117 after report of interest from Merck in cancer assets
Premium
The Fly
Inhibrx up 39% at $117 after report of interest from Merck in cancer assets
3d ago
Inhibrx Biosciences Highlights Promising Ozekibart Colorectal Cancer Data
Premium
Company Announcements
Inhibrx Biosciences Highlights Promising Ozekibart Colorectal Cancer Data
4d ago
Inhibrx Biosciences Highlights 2026 Pipeline and Strategy
PremiumCompany AnnouncementsInhibrx Biosciences Highlights 2026 Pipeline and Strategy
2M ago
Premium
Company Announcements
Inhibrx Biosciences Updates on Clinical Trials Progress
4M ago
Inhibrx provides update on INBRX-106 Phase 2/3 clinical trial
Premium
The Fly
Inhibrx provides update on INBRX-106 Phase 2/3 clinical trial
4M ago
PremiumCompany AnnouncementsInhibrx’s Promising Study on INBRX-106 for Advanced Head and Neck Cancer
6M ago
Premium
Company Announcements
Inhibrx Biosciences Advances Cancer Treatment with INBRX-106 Study Update
6M ago
Premium
Company Announcements
Inhibrx’s Phase 2 Study on INBRX-109: A Potential Breakthrough in Chondrosarcoma Treatment
6M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100